Openly accessible

Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?

Mc Namara, Kevin, Alzubaidi, Hamzah and Jackson, John Keith 2019, Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?, Integrated pharmacy research and practice, vol. 8, pp. 1-11, doi: 10.2147/IPRP.S133088.

Attached Files
Name Description MIMEType Size Downloads

Title Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?
Author(s) Mc Namara, KevinORCID iD for Mc Namara, Kevin orcid.org/0000-0001-6547-9153
Alzubaidi, Hamzah
Jackson, John Keith
Journal name Integrated pharmacy research and practice
Volume number 8
Start page 1
End page 11
Total pages 11
Publisher Dove Medical Press
Place of publication Macclesfield, Eng.
Publication date 2019
ISSN 2230-5254
2230-5254
Keyword(s) cardiovascular risk factors
chronic disease management
disease screening
health services
preventative health
Summary Cardiovascular diseases (CVDs) are a leading cause of death globally. This article explores the evidence surrounding community pharmacist interventions to reduce cardiovascular events and related mortality and to improve the management of CVD risk factors. We summarize a range of systematic reviews and leading randomized controlled trials and provide critical appraisal. Major observations are that very few trials directly measure clinical outcomes, potentially owing to a range of challenges in this regard. By contrast, there is an extensive, high-quality evidence to suggest that improvements can be achieved for key CVD risk factors such as hypertension, dyslipidemia, tobacco use, and elevated hemoglobin A1c. The heterogeneity of interventions tested and considerable variation of the context under which implementation occurred suggest that caution is warranted in the interpretation of meta-analyses. It is highly important to generate evidence for pharmacist interventions in developing countries where a majority of the global CVD burden will be experienced in the near future. A growing capacity for clinical registry trials and data linkage might allow future research to collect clinical outcomes data more often.
Language eng
DOI 10.2147/IPRP.S133088
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2019, Mc Namara et al.
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30119887

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 42 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 14 Mar 2019, 11:50:47 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.